Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun;175(2):429-441.
doi: 10.1007/s10549-019-05149-4. Epub 2019 Feb 12.

The effect of chemotherapy on subjective cognitive function in younger early-stage breast cancer survivors treated with chemotherapy compared to older patients

M L Gregorowitsch  1 , A Ghedri  2 , D A Young-Afat  3   4 , R Bijlsma  5 , I O Baas  5 , C van Schaik-van de Mheen  6 , M J Agterof  7 , E Göker  8 , D Ten Bokkel Huinink  9 , H J G D van den Bongard  3 , H M Verkooijen  2   10 ; UMBRELLA study group
Affiliations

The effect of chemotherapy on subjective cognitive function in younger early-stage breast cancer survivors treated with chemotherapy compared to older patients

M L Gregorowitsch et al. Breast Cancer Res Treat. 2019 Jun.

Abstract

Purpose: To evaluate the impact of chemotherapy on subjective cognitive functioning according to age in a large cohort of breast cancer patients.

Methods: Within the UMBRELLA cohort, 715 patients with early-stage primary invasive breast cancer (T1-3N0-1M0) were selected. Subjective cognitive function was assessed by means of the EORTC QLQ-C30 up to 24 months and compared between patients treated with and without chemotherapy, for three different age strata (355 patients < 55 years, 240 patients aged 55-65 years, and 120 patients > 65 years). Differences between chemotherapy and non-chemotherapy patients by age at different time points were assessed by linear mixed-effect models correcting for age, tumor stage, educational level, endocrine therapy, anxiety, and depression.

Results: In total, 979 patients from the UMBRELLA cohort were included, of which 715 (73%) responded to baseline and at least one follow-up questionnaire. Questionnaire response rates ranged between 92 and 70%. The proportion of patients treated with chemotherapy decreased with age: 64% (n = 277) in patients < 55 years, 45% (n = 107) in patients 55-65 years, and 23% (n = 27) in patients > 65 years. Chemotherapy was associated with reduced subjective cognitive functioning. The impact of chemotherapy on subjective cognitive function was most pronounced in patients < 55 years, followed by those between 55 and 65 years. In the youngest age groups, patients treated with chemotherapy had significantly lower cognitive functioning up to 24 months. In women over 65 years, subjective cognitive functioning was comparable between patients treated with and without chemotherapy.

Conclusion: This study confirms that chemotherapy is associated with impaired subjective self-reported cognitive functioning in breast cancer patients, and the effect persists at least up to 2 years after diagnosis. The impact of chemotherapy on self-reported cognitive functioning in the first 24 months is most pronounced in younger patients, especially those under 55 years of age.

Keywords: Breast cancer; Chemotherapy; Cognitive function; Patient-reported outcome.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Flowchart of patient inclusion within the UMBRELLA breast cancer cohort and response rates. Response rates were calculated based on the opportunity patients had to return the questionnaire according to their inclusion date
Fig. 2
Fig. 2
Cognitive functioning. Higher score indicates better cognitive functioning
Fig. 3
Fig. 3
Cognitive function in early-stage breast cancer patients according to chemotherapy treatment stratified by age categories and compared to the age-matched Dutch reference population. Cognitive function was assessed with the cancer questionnaire of the European Organization for Research and Treatment of Cancer (EORTC QLQ-C30). Results are presented as adjusted mean scores accompanied with 95% confidence intevals. Higher score indicates better cognitive function
See this image and copyright information in PMC

References

    1. Holzel D, Eckel R, Bauerfeind I, Baier B, Beck T, Braun M, et al. Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich Cancer Registry. J Cancer Res Clin Oncol. 2017;143(9):1701–1712. doi: 10.1007/s00432-017-2428-0. - DOI - PMC - PubMed
    1. Ganz PA, Kwan L, Castellon SA, Oppenheim A, Bower JE, Silverman DH, et al. Cognitive complaints after breast cancer treatments: examining the relationship with neuropsychological test performance. J Natl Cancer Inst. 2013;105(11):791–801. doi: 10.1093/jnci/djt073. - DOI - PMC - PubMed
    1. Boykoff N, Moieni M, Subramanian SK. Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response. J Cancer Surviv. 2009;3(4):223–232. doi: 10.1007/s11764-009-0098-x. - DOI - PMC - PubMed
    1. Winocur G, Johnston I, Castel H. Chemotherapy and cognition: International Cognition and Cancer Task Force recommendations for harmonising preclinical research. Cancer Treat Rev. 2018;69:72–83. doi: 10.1016/j.ctrv.2018.05.017. - DOI - PubMed
    1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432–444. doi: 10.1016/S0140-6736(11)61625-5. - DOI - PMC - PubMed

MeSH terms